[{"indications": "Indications\u00a0skin manifestations of cutaneous T-cell lymphoma refractory to previous\r\nsystemic treatment", "name": "BEXAROTENE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.5 Other antineoplastic drugs", "Bexarotene", "BEXAROTENE"], "cautions": "Cautions\u00a0see section 8.1 and notes above; hyperlipidaemia (avoid if uncontrolled), hypothyroidism (avoid if uncontrolled); hypersensitivity to retinoids; avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (bexarotene)", "side-effects": "Side-effects\u00a0see section 8.1 and notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106421.htm", "doses": ["Initially 300\u00a0mg/m2 daily as a single dose\r\nwith a meal; adjust dose according to response"], "pregnancy": "Pregnancy\u00a0avoid; manufacturer advises effective contraception\r\nduring and for at least 1 month after treatment in men or women; see\r\nalso Pregnancy and Reproductive\r\nFunction"}]